Chromocell Therapeutics(CHRO) - 2025 Q3 - Quarterly Results

Financial Performance - Pelthos Therapeutics reported net product revenue of $7.1 million from ZELSUVMI in Q3 2025, with 2,716 units prescribed by 1,169 unique prescribers[1][4][6]. - Cash position as of September 30, 2025, was $14.2 million, with total current assets amounting to $49.8 million[6][8]. - Selling, general and administrative expenses for Q3 2025 were $19.6 million, reflecting costs associated with supporting ZELSUVMI's sales growth[6][10]. - The net loss for Q3 2025 was $16.2 million, equating to a net loss of $5.30 per share[6][10]. - Adjusted EBITDA for Q3 2025 was reported at $(11.5) million, indicating ongoing investment in growth despite losses[11][13]. - Cost of goods sold for Q3 2025 was $2.3 million, with adjustments leading to an adjusted COGs of $413,000[6][17]. Strategic Initiatives - The company closed a merger with Channel Therapeutics Corporation and LNHC, Inc., raising $50.1 million in an equity private placement to support ZELSUVMI's launch[4][6]. - The acquisition of XEPI, a novel FDA-approved treatment for impetigo, was completed in November 2025, addressing a significant unmet need in pediatric skin infections[4][5]. - Pelthos is positioned to leverage synergies between ZELSUVMI and XEPI to enhance revenue through existing commercial relationships[5][6]. - Pelthos expects the acquisition of XEPI to enhance existing commercial operations and provide additional revenue opportunities through cost synergies[21]. - The company believes it is well-positioned to capitalize on large addressable markets with both ZELSUVMI and XEPI[21]. Product Performance - The company anticipates continued strong growth for ZELSUVMI, with 2,189 units prescribed in October 2025 alone[3][4]. - Pelthos Therapeutics' lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, was approved by the U.S. FDA in 2024 for treating molluscum contagiosum[20]. - The company anticipates continued growth of ZELSUVMI in Q4 2025[21]. Risks and Considerations - Risks include reliance on collaborative partners for revenue projections and potential delays in product development and regulatory approvals[21]. - Adjusted EBITDA and Adjusted COGs are considered useful measures for period-to-period comparisons of business performance[21].